Comparison of Patients from Nigeria and the USA Highlights Modifiable Risk Factors for Sickle Cell Anemia Complications

References

• Serjeant GR, Serjeant BE. Sickle Cell Disease, 3rd ed. Oxford, UK: Oxford University Press, 2001
   Google Scholar
• Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(4 Suppl):S512–S521
   PubMed Web of Science ®Google Scholar
• Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639–1644
   PubMed Web of Science ®Google Scholar
• Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991;325(1):11–16
   PubMed Web of Science ®Google Scholar
• Castro O, Brambilla DJ, Thorington B, et al. The acute chest syndrome in sickle cell disease: Incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood. 1994;84(2):643–649
   PubMed Web of Science ®Google Scholar
• Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA. 2003;289(13):1645–1651
   PubMed Web of Science ®Google Scholar
• Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332(20):1317–1322
   PubMed Web of Science ®Google Scholar
• Pegelow CH, Colangelo L, Steinberg M, et al. Natural history of blood pressure in sickle cell disease: Risks for stroke and death associated with relative hypertension in sickle cell anemia. Am J Med. 1997;102(2):171–177
   PubMed Web of Science ®Google Scholar
• Gordeuk VR, Sachdev V, Taylor JG, et al. Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiency. Am J Hematol. 2008;83(1):15–18
   PubMed Web of Science ®Google Scholar
• Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: Rates and risk factors. Blood. 1998;91(1):288–294
   PubMed Web of Science ®Google Scholar
• Lamarre Y, Lalanne-Mistrih ML, Romana M, et al. Male gender, increased blood viscosity, body mass index and triglyceride levels are independently associated with systemic relative hypertension in sickle cell anemia. PloS One. 2013;8(6):e66004
   PubMed Web of Science ®Google Scholar
• Desai PC, Deal AM, Brittain JE, et al. Decades after the cooperative study: A re-examination of systemic blood pressure in sickle cell disease. Am J Hematol. 2012;87(10):E65–E68
   Web of Science ®Google Scholar
• Oguanobi NI, Onwubere BJ, Ibegbulam OG, et al. Arterial blood pressure in adult Nigerians with sickle cell anemia. J Cardiol. 2010;56(3):326–331
   PubMed Web of Science ®Google Scholar
• Cooper R, Rotimi C, Ataman S, et al. The prevalence of hypertension in seven populations of west African origin. Am J Public Health. 1997;87(2):160–168
   PubMedGoogle Scholar
• Rosenthal J, Rodewald L, McCauley M, et al. Immunization coverage levels among 19- to 35-month-old children in 4 diverse, medically underserved areas of the United States. Pediatrics. 2004;113(4):e296–e302
   PubMed Web of Science ®Google Scholar
• Fatiregun AA, Adebowale AS, Ayoka RO, Fagbamigbe AF. Assessing full immunisation coverage using lot quality assurance sampling in urban and rural districts of southwest Nigeria. Trans Roy Soc Trop Med Hyg. 2013;107(11):731–740
   PubMedGoogle Scholar
• Barlow SE, Expert C. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics. 2007;120(Suppl 4):S164–S192
   PubMed Web of Science ®Google Scholar
• The National Institutes of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. (http://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf.) National Institutes of Health, US Department of Health and Human Services, 1998 (accessed October 17 2013)
   Google Scholar
• The National Institutes of Health. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (http://nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf.) National Institutes of Health, US Department of Health and Human Services, 2003 (accessed October 17 2013)
   Google Scholar
• Wilson PW, D’Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: The Framingham experience. Arch Internal Med. 2002;162(16):1867–1872
   PubMedGoogle Scholar
• Abo-Zenah H, Moharram M, El Nahas AM. Cardiorenal risk prevalence in sickle cell hemoglobinopathy. Nephron Clin Pract. 2009;112(2):c98–c106
   PubMedGoogle Scholar
• Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med. 1986;314(25):1593–1599
   PubMed Web of Science ®Google Scholar
• Ammann AJ, Addiego J, Wara DW, et al. Polyvalent pneumococcal-polysaccharide immunization of patients with sickle-cell anemia and patients with splenectomy. N Engl J Med. 1977;297(17):897–900
   PubMed Web of Science ®Google Scholar
• Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44(11):1428–1433
   PubMed Web of Science ®Google Scholar
• Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol. 2010;85(6):403–408
   PubMed Web of Science ®Google Scholar
• Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: Results of a 17-year, single-center trial (LaSHS). Blood. 2010;115(12):2354–2363
   PubMed Web of Science ®Google Scholar
• Galadanci N, Wudil BJ, Balogun TM, et al. Current sickle cell disease management practices in Nigeria. Int Health. 2014;6(1):23–28
   PubMed Web of Science ®Google Scholar
• Yetunde A, Anyaegbu CC. Profile of the Nigerian sickle cell anaemia patients above 30 years of age. Cent Afr J Med. 2001;47(4):108–111
   PubMedGoogle Scholar
• Enosolease ME, Ejele OA, Awodu OA. The influence of foetal haemoglobin on the frequency of vaso-occlusive crisis in sickle cell anaemia patients. Niger Postgrad Med J. 2005;12(2):102–105
   PubMedGoogle Scholar
• Fatunde OJ, Scott-Emuakpor AB. Foetal haemoglobin in Nigerian children with sickle cell anaemia. Effect on haematological parameters and clinical severity. Trop Geogr Med. 1992;44(3):264–266
   PubMedGoogle Scholar
• Powars DR, Weiss JN, Chan LS, Schroeder WA. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? Blood. 1984;63(4):921–926
   PubMed Web of Science ®Google Scholar
• Lagunju IA, Brown BJ. Adverse neurological outcomes in Nigerian children with sickle cell disease. Int J Hematol. 2012;96(6):710–718
   PubMed Web of Science ®Google Scholar
• Fatunde OJ, Adamson FG, Ogunseyinde O, et al. Stroke in Nigerian children with sickle cell disease. Afr J Med Med Sci. 2005;34(2):157–160
   PubMedGoogle Scholar